+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Respiratory Distress Syndrome Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

  • ID: 4768002
  • Report
  • April 2019
  • Region: Global
  • 248 pages
  • VPA Research

FEATURED COMPANIES

  • Allergan Plc
  • Bayer AG
  • Chiesi Farmaceutici SpA
  • F. Hoffmann-La Roche Ltd
  • Faron Pharmaceuticals Oy
  • GlaxoSmithKline Plc
The global clinical trial report- “2019 Respiratory Distress Syndrome Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Respiratory Distress Syndrome. It presents in-depth analysis of Respiratory Distress Syndrome clinical trials across markets and companies. The research work is for providing complete understanding into trends in Respiratory Distress Syndrome.

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Respiratory Distress Syndrome clinical trials by:
  • Current Trial Status
  • Type of the trial
  • Sponsor Type
  • Enrollment Trends
  • Region
  • Countries
  • Trial Phase
The report also identifies the potential drug candidates under development for treatment of Respiratory Distress Syndrome

The research work is prepared through extensive and continuous research on Respiratory Distress Syndrome trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:
  • All major trials from 2010 to 2019 and planned trials are included in the report scope.
  • Drug candidates currently being researched for administering Respiratory Distress Syndrome patients are identified
  • The report includes panorama of Respiratory Distress Syndrome clinical trials across the globe
  • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
  • Companies and universities focusing on Respiratory Distress Syndrome clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
  • Average Enrollment number, insights into enrollment trends, company wise enrollment are included
  • Both interventional and observational studies are analyzed
  • News and latest developments for the past one year are presented in the report
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Allergan Plc
  • Bayer AG
  • Chiesi Farmaceutici SpA
  • F. Hoffmann-La Roche Ltd
  • Faron Pharmaceuticals Oy
  • GlaxoSmithKline Plc
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Respiratory Distress Syndrome Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Respiratory Distress Syndrome Clinical Trials by Region
2.2.2 Average Enrollment of Respiratory Distress Syndrome Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Respiratory Distress Syndrome Treatment, 2019

3. Region wise Respiratory Distress Syndrome Clinical Trials
3.1 Asia Pacific Respiratory Distress Syndrome Clinical Trials by Country
3.2 Europe Respiratory Distress Syndrome Clinical Trials by Country
3.3 North America Respiratory Distress Syndrome Clinical Trials by Country
3.4 Middle East and Africa Respiratory Distress Syndrome Clinical Trials by Country
3.5 South and Central America Respiratory Distress Syndrome Clinical Trials by Country

4. Respiratory Distress Syndrome Clinical Trial Trends
4.1 Start Year wise Respiratory Distress Syndrome Clinical Trials
4.2 Phase wise Respiratory Distress Syndrome Clinical Trials
4.3 Trial Status wise Respiratory Distress Syndrome Clinical Trials
4.4 Trial Type wise Respiratory Distress Syndrome Clinical Trials

5. Respiratory Distress Syndrome Average Enrollment Trends
5.1 Average Enrollment in Respiratory Distress Syndrome Trials by Year
5.2 Average Enrollment in Respiratory Distress Syndrome Trials by Phase
5.3 Average Enrollment in Respiratory Distress Syndrome Trials by Status
5.4 Average Enrollment in Respiratory Distress Syndrome Trials by Type of Trial

6. Companies Participating in Respiratory Distress Syndrome Clinical Trials
6.1 Respiratory Distress Syndrome Trials by Sponsor Type
6.2 Respiratory Distress Syndrome Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7. Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Respiratory Distress Syndrome Trials- Phase 1
7.2 Respiratory Distress Syndrome Trials- Phase 2
7.3 Respiratory Distress Syndrome Trials- Phase 3
7.4 Respiratory Distress Syndrome Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Respiratory Distress Syndrome Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific - Country wise Respiratory Distress Syndrome Clinical Trials and Enrolment
Figure 5: Europe - Country wise Respiratory Distress Syndrome Clinical Trials and Enrolment
Figure 6: Middle East Africa - Country wise Respiratory Distress Syndrome Clinical Trials and Enrolment
Figure 7: North America - Country wise Respiratory Distress Syndrome Clinical Trials and Enrolment
Figure 8: South and Central America - Country wise Respiratory Distress Syndrome Clinical Trials and Enrolment
Figure 9: Respiratory Distress Syndrome Clinical Trials by Phase
Figure 10: Respiratory Distress Syndrome Clinical Trials by Trial Status
Figure 11: Respiratory Distress Syndrome Clinical Trials by Type
Figure 12: Respiratory Distress Syndrome Clinical Trials by Sponsor Type
Figure 13: Respiratory Distress Syndrome Clinical Trials by Leading Sponsors
Figure 14: Respiratory Distress Syndrome Average Enrollment by Phase
Figure 15: Respiratory Distress Syndrome Average Enrollment by Trial Status
Figure 16: Respiratory Distress Syndrome Average Enrollment by Type
Figure 17: Respiratory Distress Syndrome- Average Enrolment by Type of Sponsors
Figure 18: Respiratory Distress Syndrome- Enrolment by Leading Sponsors
Figure 19: Research Methodology

List of Tables
Table 1: Respiratory Distress Syndrome Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific - Country wise Respiratory Distress Syndrome Clinical Trials and Enrolment
Table 5: Europe - Country wise Respiratory Distress Syndrome Clinical Trials and Enrolment
Table 6: Middle East Africa - Country wise Respiratory Distress Syndrome Clinical Trials and Enrolment
Table 7: North America - Country wise Respiratory Distress Syndrome Clinical Trials and Enrolment
Table 8: South and Central America - Country wise Respiratory Distress Syndrome Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Respiratory Distress Syndrome Average Enrollment by Phase
Table 15: Respiratory Distress Syndrome Average Enrollment by Trial Status
Table 16: Respiratory Distress Syndrome Average Enrollment by Type
Table 17: Respiratory Distress Syndrome- Average Enrolment by Type of Sponsors
Table 18: Respiratory Distress Syndrome- Enrolment by Leading Sponsors
Note: Product cover images may vary from those shown
  • Allergan Plc
  • Bayer AG
  • Chiesi Farmaceutici SpA
  • F. Hoffmann-La Roche Ltd
  • Faron Pharmaceuticals Oy
  • GlaxoSmithKline Plc
  • MallInckrodt Plc
  • Savara Inc
  • THERAMetrics holding AG
  • Windtree Therapeutics Inc
Note: Product cover images may vary from those shown
Adroll
adroll